A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Generalized Pustular Psoriasis

In brief

This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost clear when they join the study. The purpose of the study is to test 3 different doses of a medicine called spesolimab and to see whether it helps to prevent GPP flare-ups. Participants are put into 4 groups by chance. Three groups get different doses of spesolimab. The fourth group gets a placebo. Placebo looks like spesolimab but does not contain any medicine. Spesolimab and placebo are given as an injection under the skin. Participants are in the study for about 1 year and 4 months. During this time, they visit the study site about 15 times. For the first 11 months, participants get spesolimab or placebo injections every month. At the study visits, the doctors check participants' skin for signs of a new GPP flare-up. The doctors also check the general health of the participants. If a participant has a GPP flare-up during the study, more visits may be necessary. In case of a flare-up, participants get a dose of spesolimab as an infusion into a vein.

Key facts

Study ID

NCT04399837

Run by

Boehringer Ingelheim

People needed

123

Starts

2020-06-04

Expected to finish

2022-11-23

Last updated by the study team

2025-10-20

Who can join

Age: 12 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a known and documented history of GPP per ERASPEN criteria (see Section 3.3.1) regardless of IL36RN mutation status, with at least 2 presentations of moderate to severe GPP flares with fresh pustulation (new appearance or worsening) in the past.
• Patients with a GPPGA score of 0 or 1 at screening and randomization.
• Patients who are not on concomitant GPP treatment at time of randomization (V2) must have had at least two presentations of moderate to severe GPP flare in the past year, at least one of which had evidence of either fever and/or elevated CRP and/or elevated WBC, and/or asthenia and/or myalgia.
• Patients who are not on concomitant GPP treatment at time of randomization (V2) but who were on concomitant GPP treatment until shortly before randomization (V2) (≤ 12 weeks before randomization), these patients must have a history of flaring while on concomitant treatment for GPP or in case of dose reduction or discontinuation of their concomitant medication.
• Patients who are on concomitant treatment regimen with retinoids and/or methotrexate and/or cyclosporine must stop at the day of randomization (V2). These patients must have a history of flaring while on concomitant treatment for GPP or in case of dose reduction or discontinuation of these concomitant medications.
• Male or female patients, aged 12 to 75 years at screening. For all patients, a minimum weight of 40 kg is required.
• Signed and dated written informed consent and assent in accordance with ICH-GCP and local legislation prior to admission in the trial.
• Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the CTP as well as in the patient, parent(s) (or patient's legal guardian) information.

You may not qualify if…

• Patients with SAPHO (Synovitis-acne-pustulosis-hyperostosis-osteitis) syndrome.
• Patients with primary erythrodermic psoriasis vulgaris.
• Severe, progressive, or uncontrolled hepatic disease, defined as >3-fold Upper Limit of Normal (ULN) elevation in Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) or alkaline phosphatase, or >2-fold ULN elevation in total bilirubin.
• Treatment with:
• Any restricted medication as specified in the CTP, or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator.
• Any prior exposure to BI 655130 or another IL36R inhibitor biologic.
• Increased risk of infectious complications (e.g. recent pyogenic infection, any congenital or acquired immunodeficiency (e.g. HIV), past organ or stem cell transplantation), as assessed by the investigator.
• Relevant chronic or acute infections including active tuberculosis, human immunodeficiency virus (HIV) infection or viral hepatitis at the time of randomization. A patient can be re-screened if the patient was treated and is cured from the acute infection.
• Active or Latent Tuberculosis (TB):
• Patients with active tuberculosis should be excluded
• Patients with a positive QuantiFERON® (or if applicable, T-Spot®) TB test during screening are excluded, unless the patient had previous diagnosis of active or latent TB and has completed appropriate treatment per the discretion of the local investigator within the last 3 years and at the latest at the time of screening (i.e. 2 to 4 weeks before study drug administration); patients may be re-screened once to meet this criterion)
• Patients with suspected false positive or indeterminate QuantiFERON® (or if applicable, T-Spot®) TB result may be re-tested once
• If QuantiFERON® (or if applicable, T-Spot®) TB testing is not available or provides indeterminate results after repeat testing, a tuberculin skin test (TST) can be performed: A TST reaction of ≥10mm (≥5mm if receiving ≥15mg/d prednisone or its equivalent) is considered positive.
• History of allergy/hypersensitivity to the systemically administered trial medication agent or its excipients.
• Further exclusion criteria apply.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States
• Buenos Aires Skin S.A. — CABA, Argentina
• Hospital Italiano de Buenos Aires — CABA, Argentina
• Brussels - UNIV Saint-Luc — Brussels, Belgium
• Clínica Dermacross S.A. — Vitacura, Chile
• Sun yet-sen Memorial Hospital, Sun yet-sen Univesity — Guangzhou, China
• The Second Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, China
• Shanghai Skin Disease Hospital — Shanghai, China
• Huashan Hospital, Fudan University — Shanghai, China
• The First Hospital of China Medical University — Shenyang, China
• Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital — Tianjin, China
• Second Affiliated Hospital of Xi'an JiaoTong University — Xi'an, China
• HOP l'Archet — Nice, France
• HOP Saint-Louis — Paris, France
• Fachklinik Bad Bentheim — Bad Bentheim, Germany
• Universitätsklinikum Bonn AöR — Bonn, Germany
• Universitätsklinikum Frankfurt — Frankfurt am Main, Germany
• Klinikum der Universität München - Campus Innenstadt — München, Germany
• Universitätsklinikum Münster — Münster, Germany
• Klinikum Oldenburg AöR — Oldenburg, Germany
• Universitätsklinikum Würzburg AÖR — Würzburg, Germany
• General Hospital of Thessaloniki "Ippokrateio" — Thessaloniki, Greece
• Istituto Clinico Humanitas — Rozzano (MI), Italy
• Nagoya City University Hospital — Aichi, Nagoya, Japan
• Oakland Hills Dermatology — Auburn Hills, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.